NATESTO® is the first and only nasal testosterone replacement therapy available in Canada and in the U.S. for the treatment of male hypogonadism.
Male hypogonadism, also known as "Low T", refers to a condition in which the body does not produce a sufficient level of testosterone, an important hormone. You can be born with male hypogonadism, or it can develop later in life from injury or infection. The effects — and what you can do about them — depend on the cause and at what point in life male hypogonadism occurs. Some types of male hypogonadism can be treated with testosterone replacement therapy.1 Low T is often misdiagnosed as a host of other conditions, including depression and erectile dysfunction. A diagnosis of hypogonadism depend on an assessment of symptoms by a healthcare professional, and the results of blood tests that measure testosterone levels. Current treatment guidelines focus on the restoration of the physiological testosterone level through the use of exogenous testosterone preparations.2
- Mayo Clinic: http://www.mayoclinic.org/diseases-conditions/male-hypogonadism/basics/definition/con-20014235. Accessed June 30, 2015.
- Mayo Clinic: http://www.mayoclinic.org/diseases-conditions/male-hypogonadism/basics/tests-diagnosis/con-20014235. Accessed June 30, 2015.
NATESTO® is Available in the U.S.
NATESTO® was approved by the United States Food and Drug Administration (‘FDA’) in May 2014 for replacement therapy in men for conditions associated with a deficiency or absence of endogenous testosterone (hypogonadism).
For further information on NATESTO® in the U.S. (including the product label and prescribing information), please see the FDA website, or visit www.NATESTO.com
NATESTO® is Now Available in Canada
NATESTO® was approved by Health Canada in January 2016 for replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone (hypogonadism).
Click the below link to view the NATESTO® Product Monograph and Patient Information.